BRCA1 and hereditary cancer: There are data suggesting that the best responders to PARPi and platinum compounds are accumulated mainly within patients with BRCA1/2-driven hereditary cancers, while sporadic tumors with evidences for BRCAness/HRD phenotype often demonstrate less pronounced although still medically meaningful response to BRCA1/2-specific therapy [4, 42, 58].